Literature DB >> 21317394

NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.

Maria Salagianni1, Eftychia Lekka, Ardiana Moustaki, Eleni G Iliopoulou, Constantin N Baxevanis, Michael Papamichail, Sonia A Perez.   

Abstract

Previous work from our laboratory showed that hydrocortisone (HC) combined with IL-15 induces expansion of activated human NK cells. We set up an experimental tumor model to evaluate the use of adoptively transferred, HC plus IL-15 (HC/IL-15)-activated and -expanded murine NK cells in the treatment of syngeneic mice carrying established lung metastases of the CT26 transplantable tumor. We also examined the effect of denileukin diftitox (Ontak) on the depletion of regulatory T cells to enhance the in vivo antitumor immunity induced by the adoptively transferred NK cells. Our results clearly demonstrate that murine DX5(+) NK cells are largely expanded in the presence of IL-15 plus HC while retaining intact their functional status. Moreover, when intravenously infused, they mediated significant antitumor responses against CT26 lung tumors in syngeneic BALB/c animals that were further enhanced upon pretreatment of the tumor-bearing animals with Ontak. Total splenocytes and isolated splenic T cells from NK-treated mice responded in vitro against CT26 tumor cells as evidenced by IFN-γ-based ELISPOT, proliferation, and cytotoxicity assays. Importantly, animals treated with Ontak plus adoptive transfer of HC/IL-15-expanded NK cells significantly retarded CT26 tumor growth after a rechallenge with the same tumor s.c. in their flanks. Taken altogether, our data suggest that NK cell adoptive transfer can trigger adaptive antitumor T cell responses, and regulatory T cell depletion by Ontak is mandatory for enabling HC/IL-15-activated NK cells to promote long-lasting adaptive antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317394     DOI: 10.4049/jimmunol.1000652

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Regulatory T cells and Th17 cells in viral infections: implications for multiple sclerosis and myocarditis.

Authors:  Nicholas E Martinez; Fumitaka Sato; Eiichiro Kawai; Seiichi Omura; Robert P Chervenak; Ikuo Tsunoda
Journal:  Future Virol       Date:  2012-06       Impact factor: 1.831

2.  Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells.

Authors:  Jaclyn Stromp Peraino; Marian Schenk; Guoying Li; Huiping Zhang; Evan A Farkash; David H Sachs; Christene A Huang; Raimon Duran-Struuck; Zhirui Wang
Journal:  J Immunol Methods       Date:  2013-09-18       Impact factor: 2.303

Review 3.  Interleukin-15 biology and its therapeutic implications in cancer.

Authors:  Jason C Steel; Thomas A Waldmann; John C Morris
Journal:  Trends Pharmacol Sci       Date:  2011-10-25       Impact factor: 14.819

Review 4.  Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy.

Authors:  Christoph Domschke; Andreas Schneeweiss; Stefan Stefanovic; Markus Wallwiener; Joerg Heil; Joachim Rom; Christof Sohn; Philipp Beckhove; Florian Schuetz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

5.  Rapid development of exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells.

Authors:  Saar Gill; Adrianne E Vasey; Alysha De Souza; Jeanette Baker; Aaron T Smith; Holbrook E Kohrt; Mareike Florek; Kenneth D Gibbs; Keri Tate; David S Ritchie; Robert S Negrin
Journal:  Blood       Date:  2012-04-27       Impact factor: 22.113

Review 6.  Use of allogeneic NK cells for cancer immunotherapy.

Authors:  Melissa A Geller; Jeffrey S Miller
Journal:  Immunotherapy       Date:  2011-12       Impact factor: 4.196

Review 7.  T-cell tolerance in cancer.

Authors:  Junmei Wang; Anupama Sahoo; Roza Nurieva
Journal:  Immunotherapy       Date:  2013-05       Impact factor: 4.196

8.  Regulation of inflammatory biomarkers by intravenous methylprednisolone in pediatric ARDS patients: Results from a double-blind, placebo-controlled randomized pilot trial.

Authors:  Andreas Schwingshackl; Dai Kimura; Cynthia R Rovnaghi; Jordy S Saravia; Stephania A Cormier; Bin Teng; Alina N West; Umberto G Meduri; Kanwaljeet J S Anand
Journal:  Cytokine       Date:  2015-11-03       Impact factor: 3.861

9.  Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.

Authors:  Yohei Yamada; Akihiro Aoyama; Georges Tocco; Svjetlan Boskovic; Ognjenka Nadazdin; Alessandro Alessandrini; Joren C Madsen; A Benedict Cosimi; Gilles Benichou; Tatsuo Kawai
Journal:  J Immunol       Date:  2012-05-14       Impact factor: 5.422

10.  New insights into the role of NK cells in cancer immunotherapy.

Authors:  Maria Salagianni; Constantin N Baxevanis; Michael Papamichail; Sonia A Perez
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.